» Articles » PMID: 35461756

Genomic and Epigenomic Profile of Thyroid Cancer

Overview
Publisher Elsevier
Specialty Endocrinology
Date 2022 Apr 24
PMID 35461756
Authors
Affiliations
Soon will be listed here.
Abstract

Thyroid cancer is the most common malignancy of the endocrine system, and its incidence has been steadily increasing. Advances in sequencing have allowed analysis of the entire cancer genome, and has provided new information on the genetic lesions and modifications responsible for the onset, progression, dedifferentiation and metastasis of thyroid carcinomas. Moreover, integrated genomics has advanced our understanding of the development of cancer and its behavior, and has facilitated the identification of new genetic mutations and molecular pathways. The functional analysis of epigenetic modifications, such as DNA methylation, histone acetylation and non-coding RNAs, have contributed to define new regulatory mechanisms that control cell malignancy in thyroid cancer, especially aggressive forms. Here we review the most recent advances in genomics and epigenomics of thyroid cancer, which have resulted in a new classification and interpretation of the initiation and progression of thyroid tumors, providing new tools and opportunities for further investigation and for the clinical development of new treatment strategies.

Citing Articles

Advanced pathological subtype classification of thyroid cancer using efficientNetB0.

Guo H, Zhang J, Li Y, Pan X, Sun C Diagn Pathol. 2025; 20(1):28.

PMID: 40055769 PMC: 11887243. DOI: 10.1186/s13000-025-01621-6.


Tenascin-C Potentiates Wnt Signaling in Thyroid Cancer.

Hartmann H, Loberg M, Xu G, Schwarzkopf A, Chen S, Phifer C Endocrinology. 2025; 166(3).

PMID: 39951495 PMC: 11843548. DOI: 10.1210/endocr/bqaf030.


The role of genetic and epigenetic modifications as potential biomarkers in the diagnosis and prognosis of thyroid cancer.

Sabi E Front Oncol. 2024; 14:1474267.

PMID: 39558949 PMC: 11570407. DOI: 10.3389/fonc.2024.1474267.


Molecular Markers in Follicular and Oncocytic Thyroid Carcinomas: Clinical Application of Molecular Genetic Testing.

Belaiche A, Morand G, Turkdogan S, Kang E, Forest V, Pusztaszeri M Curr Oncol. 2024; 31(10):5919-5928.

PMID: 39451745 PMC: 11506192. DOI: 10.3390/curroncol31100441.


Unveiling the Dynamic Interplay between Cancer Stem Cells and the Tumor Microenvironment in Melanoma: Implications for Novel Therapeutic Strategies.

Limonta P, Chiaramonte R, Casati L Cancers (Basel). 2024; 16(16).

PMID: 39199632 PMC: 11352669. DOI: 10.3390/cancers16162861.